Drug Profile
Research programme: drug discovery - Actelion Pharmaceuticals /Vipergen
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Vipergen ApS
- Developer Actelion Pharmaceuticals; Vipergen ApS
- Class Small molecules
- Mechanism of Action Protein modulators; Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Unspecified in Denmark
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 21 Dec 2015 Early research in Undefined indication in Denmark (unspecified route)